Roche Recalls Viracept - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Roche Recalls Viracept

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Basel, Switzerland (June 6)—Roche, in an agreement with the European Medicines Agency (EMEA, London) and the Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland), recalled all batches of “Viracept” (nelfinavir) powder and tablets in Europe and some other regions of the world.

Viracept is a protease inhibitor supplied by Roche outside the United States and Canada. The United States, Canada, and Japan are not affected by the recall.

Roche received several reports that some batches of Viracept 250-mg tablets had a strange odor. A chemical analysis of the affected tablets showed they contained higher than normal levels of methane sulfonic acid ethylester.

Ethyl mesylate is a genotoxic substance, according to EMEA. “The level of risk to patients resulting from this contamination is difficult to measure, and is currently under further evaluation,” said EMEA in a press release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here